| Date Filed | Type | Description |
| 09/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/21/2023 |
4
| Burns James William (Chief Legal Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 6,395 shares
@ $26.28, valued at
$168.1k
|
|
| 08/15/2023 |
4
| Ballal Rahul D. (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Exercised 2,302 restricted stock units
@ $0 |
|
| 08/15/2023 |
4
| Smith Cynthia (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Exercised 2,302 restricted stock units
@ $0 |
|
| 08/11/2023 |
4
| Foster-Cheek Kaye I (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 25,000 shares
@ $25.9555, valued at
$648.9k
Exercised 25,000 options to buy
@ $18.09, valued at
$452.3k
|
|
| 08/10/2023 |
4
| Goff Brian (CEO) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 10,178 shares
@ $25.48, valued at
$259.3k
Exercised 22,691 restricted stock units
@ $0 |
|
| 08/09/2023 |
4
| Washburn Theodore James Jr. (Principal Accounting Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 2,918 shares
@ $25.3927, valued at
$74.1k
|
|
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 08/02/2023 |
4
| Washburn Theodore James Jr. (Principal Accounting Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 1,232 shares
@ $26.26, valued at
$32.4k
Exercised 4,150 restricted stock units
@ $0 |
|
| 07/06/2023 |
4
| Gheuens Sarah (Chief Medical Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Granted 25,124 restricted stock units
@ $0 |
|
| 06/30/2023 |
4
| Burns James William (Chief Legal Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 1,707 shares
@ $28.36, valued at
$48.4k
Exercised 5,750 options to buy
@ $0 |
|
| 06/30/2023 |
4
| FOUSE JACQUALYN A (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 10,718 shares
@ $28.36, valued at
$304k
Exercised 23,900 options to buy
@ $0 |
|
| 06/30/2023 |
4
| Gheuens Sarah (Chief Medical Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 1,707 shares
@ $28.36, valued at
$48.4k
Exercised 5,750 options to buy
@ $0 |
|
| 06/30/2023 |
4
| Goff Brian (CEO) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 11,449 shares
@ $28.36, valued at
$324.7k
Exercised 25,528 options to buy
@ $0 |
|
| 06/30/2023 |
4
| Jones Cecilia (CFO) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 1,597 shares
@ $28.36, valued at
$45.3k
Exercised 5,380 options to buy
@ $0 |
|
| 06/30/2023 |
4
| Milanova Tsveta (Chief Commercial Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 1,618 shares
@ $28.36, valued at
$45.9k
Exercised 5,449 options to buy
@ $0 |
|
| 05/25/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/19/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
4
| Schenkein David P (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 16,363 shares
@ $22.85, valued at
$373.9k
Exercised 16,363 options to buy
@ $9.05, valued at
$148.1k
|
|
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/15/2023 |
4
| Schenkein David P (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 18,333 shares
@ $22.47, valued at
$411.9k
Sold 1,667 shares
@ $22.72, valued at
$37.9k
Exercised 20,000 options to buy
@ $9.05, valued at
$181k
|
|
| 03/07/2023 |
4
| Washburn Theodore James Jr. (Principal Accounting Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 504 shares
@ $24.29, valued at
$12.2k
|
|
| 03/01/2023 |
4
| Schenkein David P (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 20,000 shares
@ $25.37, valued at
$507.4k
Exercised 20,000 options to buy
@ $9.05, valued at
$181k
|
|
| 02/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/23/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 02/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/23/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
4
| Burns James William (Chief Legal Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 643 shares
@ $28.44, valued at
$18.3k
Exercised 1,834 restricted stock units
@ $0 |
|
|